PURPOSE: AZD1775 (adavosertib) is an inhibitor of the Wee1 kinase. In this study, we built on our preclinical studies to evaluate the safety and efficacy of AZD1775 in combination with gemcitabine and radiation in patients with newly diagnosed locally advanced pancreatic cancer. PATIENTS AND METHODS: Thirty-four patients with locally advanced pancreatic cancer were enrolled with the intention to receive four 21-day cycles of gemcitabine (1,000 mg/m2 days 1 and 8) with AZD1775 (once daily on days 1, 2, 8, and 9). Cycles 2 and 3 were administered concurrently with radiation, and cycles 5 to 8 were optional. AZD1775 was dose escalated using a time-to-event continual reassessment method on the basis of the rate of dose-limiting toxicities within the first 15 weeks of therapy. The primary objective was to determine the maximum tolerated dose of AZD1775 given in conjunction with gemcitabine and radiation. Secondary objectives were to estimate overall and progression-free survival and determine pharmacodynamic activity of AZD1775 in surrogate tissues. RESULTS: The recommended phase II dose of AZD1775 was 150 mg/d. Eight patients (24%) experienced a dose-limiting toxicity, most commonly anorexia, nausea, or fatigue. The median overall survival for all patients was 21.7 months (90% CI, 16.7 to 24.8 months), and the median progression-free survival was 9.4 months (90% CI, 8.0 to 9.9 months). Hair follicle biopsy samples demonstrated evidence of Wee1 inhibition with decreased phosphorylation of cyclin-dependent kinase 1 staining by immunohistochemistry after AZD1775 administration at the recommended phase II dose. CONCLUSION: AZD1775 in combination with gemcitabine and radiation therapy was well tolerated at a dose that produced target engagement in a surrogate tissue. The overall survival is substantially higher than prior results combining gemcitabine with radiation therapy and warrants additional investigation.
PURPOSE:AZD1775 (adavosertib) is an inhibitor of the Wee1 kinase. In this study, we built on our preclinical studies to evaluate the safety and efficacy of AZD1775 in combination with gemcitabine and radiation in patients with newly diagnosed locally advanced pancreatic cancer. PATIENTS AND METHODS: Thirty-four patients with locally advanced pancreatic cancer were enrolled with the intention to receive four 21-day cycles of gemcitabine (1,000 mg/m2 days 1 and 8) with AZD1775 (once daily on days 1, 2, 8, and 9). Cycles 2 and 3 were administered concurrently with radiation, and cycles 5 to 8 were optional. AZD1775 was dose escalated using a time-to-event continual reassessment method on the basis of the rate of dose-limiting toxicities within the first 15 weeks of therapy. The primary objective was to determine the maximum tolerated dose of AZD1775 given in conjunction with gemcitabine and radiation. Secondary objectives were to estimate overall and progression-free survival and determine pharmacodynamic activity of AZD1775 in surrogate tissues. RESULTS: The recommended phase II dose of AZD1775 was 150 mg/d. Eight patients (24%) experienced a dose-limiting toxicity, most commonly anorexia, nausea, or fatigue. The median overall survival for all patients was 21.7 months (90% CI, 16.7 to 24.8 months), and the median progression-free survival was 9.4 months (90% CI, 8.0 to 9.9 months). Hair follicle biopsy samples demonstrated evidence of Wee1 inhibition with decreased phosphorylation of cyclin-dependent kinase 1 staining by immunohistochemistry after AZD1775 administration at the recommended phase II dose. CONCLUSION:AZD1775 in combination with gemcitabine and radiation therapy was well tolerated at a dose that produced target engagement in a surrogate tissue. The overall survival is substantially higher than prior results combining gemcitabine with radiation therapy and warrants additional investigation.
Authors: Mustafa Suker; Berend R Beumer; Eran Sadot; Lysiane Marthey; Jason E Faris; Eric A Mellon; Bassel F El-Rayes; Andrea Wang-Gillam; Jill Lacy; Peter J Hosein; Sing Yu Moorcraft; Thierry Conroy; Florian Hohla; Peter Allen; Julien Taieb; Theodore S Hong; Ravi Shridhar; Ian Chau; Casper H van Eijck; Bas Groot Koerkamp Journal: Lancet Oncol Date: 2016-05-06 Impact factor: 41.316
Authors: James D Murphy; Saroja Adusumilli; Kent A Griffith; Michael E Ray; Mark M Zalupski; Theodore S Lawrence; Edgar Ben-Josef Journal: Int J Radiat Oncol Biol Phys Date: 2007-03-26 Impact factor: 7.038
Authors: Edgar Ben-Josef; Mathew Schipper; Isaac R Francis; Scott Hadley; Randall Ten-Haken; Theodore Lawrence; Daniel Normolle; Diane M Simeone; Christopher Sonnenday; Ross Abrams; William Leslie; Gazala Khan; Mark M Zalupski Journal: Int J Radiat Oncol Biol Phys Date: 2012-04-27 Impact factor: 7.038
Authors: C J McGinn; M M Zalupski; I Shureiqi; J M Robertson; F E Eckhauser; D C Smith; D Brown; G Hejna; M Strawderman; D Normolle; T S Lawrence Journal: J Clin Oncol Date: 2001-11-15 Impact factor: 44.544
Authors: Leslie A Parsels; Meredith A Morgan; Daria M Tanska; Joshua D Parsels; Brian D Palmer; R John Booth; William A Denny; Christine E Canman; Alan J Kraker; Theodore S Lawrence; Jonathan Maybaum Journal: Mol Cancer Ther Date: 2009-01 Impact factor: 6.261
Authors: Giulia Petroni; Lewis C Cantley; Laura Santambrogio; Silvia C Formenti; Lorenzo Galluzzi Journal: Nat Rev Clin Oncol Date: 2021-11-24 Impact factor: 66.675
Authors: Daniel C Moreira; Sujatha Venkataraman; Apurva Subramanian; John Desisto; Ilango Balakrishnan; Eric Prince; Angela Pierce; Andrea Griesinger; Adam Green; Charles G Eberhardt; Nicholas K Foreman; Rajeev Vibhakar Journal: J Neurooncol Date: 2020-03-16 Impact factor: 4.130
Authors: Linlin Yang; Changxian Shen; Cory J Pettit; Tianyun Li; Andrew J Hu; Eric D Miller; Junran Zhang; Steven H Lin; Terence M Williams Journal: Clin Cancer Res Date: 2020-03-27 Impact factor: 12.531
Authors: Leslie A Parsels; Qiang Zhang; David Karnak; Joshua D Parsels; Kwok Lam; Henning Willers; Michael D Green; Alnawaz Rehemtulla; Theodore S Lawrence; Meredith A Morgan Journal: Int J Radiat Oncol Biol Phys Date: 2021-08-01 Impact factor: 7.038
Authors: Cyrus Chargari; Antonin Levy; Xavier Paoletti; Jean-Charles Soria; Christophe Massard; Ralph R Weichselbaum; Eric Deutsch Journal: Clin Cancer Res Date: 2020-05-14 Impact factor: 12.531